529
Participants
Start Date
December 28, 2023
Primary Completion Date
March 29, 2024
Study Completion Date
May 31, 2024
Rcombinant botulinum neurotoxin type A for injection (YY001)
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
OnabotulinumtoxinA
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Placebo
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Guangdong Second People's Hospital, Guangzhou
Nanfang Hospital, Southern Medical University, Guangzhou
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
The Second Affiliated Hospital Of Xi'an Jiaotong University, Xian
West China School of Medicine/West China Hospital of Sichuan University, Chengdu
Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou
Zhejiang Provincial People's Hospital, Hangzhou
Beijing Tsinghua Changgung Hospital, Beijing
Peking Union Medical College Hospital , Chinese Academy of Medical Sciences, Beijing
Peking University First Hospital, Beijing
Peking University Third Hospital, Beijing
Plastic Surgery Hospital, Chinese Academy of Medical Science, Beijing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Tianjin Medical University General Hospital, Tianjin
The Third Xiangya Hospital of Central South University, Changsha
Chongqing Claruvis Pharmaceutical Co., Ltd.
INDUSTRY